BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Lab Test Results of Patented Biopesticide Achieve 100% Control of Root-Rot Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced successful test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”). The tests, conducted via an independent third-party facility, achieved 100% control of the root-rot disease Aphanomyces zoospores at economic application rates within 24 hours; Aphanomyces is a soil-borne disease that destroys key plant-based protein crops such as peas, lentils and legumes; current treatments are unable to control the disease. MustGrow next plans to test its proprietary biopesticide in larger-scale greenhouse and field settings. The company’s safe and effective organic biopesticide is plant based, using the mustard seed’s natural defense mechanism to control diseases, pests and weeds. Aphanomyces is a water-mold pathogen that destroys peas, lentils and other legumes, which are often referred to as pulse crops. Studies indicate that at least $20 million of pulse crops are lost annually in Canada as a result of Aphanomyces; worldwide that figure reaches $100 million. “It is great to see MustGrow’s mustard plant-based biopesticide continue to perform, particularly with 100% disease control measured at exceptionally low application rates,” said MustGrow COO Colin Bletsky. “The level of control of hard-to-kill diseases we continue to achieve combined with the beneficial properties of our product for soil health provide a great opportunity for improved yields for farmers and a more robust food supply. I am very hopeful that we can potentially provide a valuable crop-protection tool for pulse crop farmers.”

To view the full press release, visit https://ibn.fm/0f4CD

About MustGrow Biologics Corp.

MustGrow is a publicly traded, agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s Pest Management Regulatory Agency (“PMRA”) as a biopesticide for high-value crops, including fruits and vegetables. MustGrow has now concentrated a liquid format, TerraMG, that with regulatory approval could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For more information about the company, please visit www.MustGrow.ca. 

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, received…

23 hours ago

BioMedNewsBreaks — Nano-X Imaging Ltd. (NASDAQ: NNOX) Strengthens UK Market Access and Hospital-Based AI Capabilities

Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), an innovative technology company, is advancing Nanox.AI’s commercial and…

1 day ago

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Completes Manufacturing of Next-Generation AI Intoxication Detection Kiosk

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…

1 day ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Expands Florida Healthcare Network With New PharmcoRx Pharmacy in Jacksonville

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

2 days ago

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first…

2 days ago

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Strong Surgeon Interest in GelrinC at International Cartilage Summit

Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions,…

3 days ago